DiaMedica Therapeutics Inc. DMAC
Set alert
9.11 USD -0.14 -1.51%
As of Nov 2, 11:26 AM ET
9.11 Day range 9.51
5.25 52-week range 10.42
- YTD
- +14.45%
- 1 year
- +29.04%
- Open
- 9.47
- Prev close
- 9.25
- Mkt cap
- 491.80M
- Vol
- 22.17K
- Avg vol
- 185.28K
- EPS
- -0.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.11
- High
- 9.51
- Forward P/E
- -7.26
- Beta
- 1.46
- Short ratio
- 3.88
- Inst. own
- 31.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 4.69
- 200-d avg
- 3.61
- 1y target
- 7.00
YTD chart
Signals (55)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| RSI: Oversold | Apr 10, 2026 | 6 months ago |
| SMA: Bearish | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Feb 26, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
Key statistics
- Market cap
- 229.84M
- Enterprise value
- 122.45M
- Trailing P/E
- 0.00
- Forward P/E
- -7.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.00
- EPS (TTM)
- -0.56
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.14M
- Total cash
- 54.05M
- Total debt
- 388.00K
- Return on equity
- -35.18%
- Shares outstanding
- 42.76M
- Short % of float
- 0.59%
- 50-day average
- 4.69
- 200-day average
- 3.61
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 -23.2% downside
Now 9.11
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.1725.
Financials — quick view
DMAC Revenue — quarterly 0
DMAC Net income — quarterly -10.15M
DMAC EPS — quarterly -0.19
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.15 | -0.15 | 0.00 | 0.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | -0.13 | +0.03 | +18.75% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| May 8, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| Mar 19, 2024 | Dec 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | init | — | Buy |
| Aug 16, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2024 | Craig-Hallum | main | Buy | Buy |
| Mar 21, 2024 | Oppenheimer | reit | Outperform | Outperform |
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- diamedica.com
News
- DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
- DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
- DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
- DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
- Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
- All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
- DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on DMAC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GIUFFRE RANDALL MICHAEL | Director | Stock Award(Grant) | Jan 1, 2024 | 411,194 |
| KELLEN SCOTT | Chief Financial Officer | Purchase | Jun 22, 2023 | 32,290 |
| KUNTZ RICHARD P | Director | Stock Award(Grant) | Jan 1, 2024 | 14,285 |
| PARSONS JAMES T CPA | Director | Stock Award(Grant) | Jan 1, 2024 | 59,937 |
| PAULS DIETRICH JOHN | Chief Executive Officer | Purchase | Jun 22, 2023 | 68,591 |
| PILNIK RICHARD D | Director | Stock Award(Grant) | Jan 1, 2024 | 278,602 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cooperman, Leon G. | 3.54% | 1,511,739 | 8.13M | Sep 29, 2024 |
| Vanguard Group Inc | 2.45% | 1,049,029 | 5.64M | Sep 29, 2024 |
| First Manhattan Co. LLC | 1.96% | 839,081 | 4.51M | Sep 29, 2024 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.13% | 482,614 | 2.59M | Sep 29, 2024 |
| Bleichroeder LP | 0.89% | 382,317 | 2.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 306,958 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.75% | 747,198 | 4.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.59% | 253,733 | 1.36M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 149,057 | 801.18K | Oct 30, 2024 |
| Jacob Discovery Fd | 0.27% | 114,730 | 616.67K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.13% | 55,116 | 296.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 48,734 | 261.94K | Oct 30, 2024 |